These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10506694)

  • 1. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project.
    Chen TH; Yen MF; Lai MS; Koong SL; Wang CY; Wong JM; Prevost TC; Duffy SW
    Cancer; 1999 Oct; 86(7):1116-28. PubMed ID: 10506694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
    Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for colorectal cancer screening.
    Bretthauer M
    Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):417-25. PubMed ID: 20833346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
    Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
    Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based estimate of the extent of colorectal cancer screening in Ontario.
    Rabeneck L; Paszat LF
    Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
    Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
    Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer test use--Maryland, 2002-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Screening of high-risk group with colorectal cancer].
    Xu AG; Yu ZJ; Zhong XH; Gan AH; Liu JH; Luo QY
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):116-8. PubMed ID: 20356496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and early detection of colorectal cancer in average risk population--summary of a meeting and the Israeli gastroenterology policy].
    Strul H; Elyakim R; Halpern Z; Arber N
    Harefuah; 2003 Mar; 142(3):223-6, 236. PubMed ID: 12696479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy.
    Haug U; Brenner H
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):422-8. PubMed ID: 15734968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].
    Takemasa I; Kikkawa N; Yasui M; Nishisho I; Fujitani K; Mishima H; Hasuike Y; Kobayashi K
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1514-8. PubMed ID: 9725042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening for colorectal cancer with an immunological fecal occult blood test].
    Fernández JL; Gallegos M; Brochero A; Arévalo C; Piccioni H; Gutiérrez Galiana H
    Acta Gastroenterol Latinoam; 1999; 29(2):73-8. PubMed ID: 10491719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal carcinoma: is screening possible?
    Bonelli L
    Tech Coloproctol; 2004 Dec; 8 Suppl 2():s267-72. PubMed ID: 15666104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
    Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
    Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer screening among first-degree relatives of colorectal cancer patients: benefits and barriers.
    Mack LA; Cook LS; Temple WJ; Carlson LE; Hilsden RJ; Paolucci EO
    Ann Surg Oncol; 2009 Aug; 16(8):2092-100. PubMed ID: 19479307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.